Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

MedWellAI (MWAI) EBITDA (2016 - 2025)

MedWellAI (MWAI) has disclosed EBITDA for 11 consecutive years, with -$265417.0 as the latest value for Q4 2025.

  • Quarterly EBITDA rose 12.88% to -$265417.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$350630.0 through Dec 2025, up 82.88% year-over-year, with the annual reading at -$761736.0 for FY2025, 91.6% up from the prior year.
  • EBITDA for Q4 2025 was -$265417.0 at MedWellAI, up from -$317727.0 in the prior quarter.
  • The five-year high for EBITDA was $11.9 million in Q2 2021, with the low at -$16.3 million in Q1 2021.
  • Average EBITDA over 5 years is -$984359.9, with a median of -$333772.0 recorded in 2021.
  • Peak annual rise in EBITDA hit 5145.71% in 2021, while the deepest fall reached 4747.28% in 2021.
  • Over 5 years, EBITDA stood at -$331865.0 in 2021, then plummeted by 84.01% to -$610649.0 in 2022, then skyrocketed by 45.03% to -$335679.0 in 2023, then rose by 9.24% to -$304648.0 in 2024, then grew by 12.88% to -$265417.0 in 2025.
  • According to Business Quant data, EBITDA over the past three periods came in at -$265417.0, -$317727.0, and $1.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.